UFT plus cisplatin for advanced gastric cancer.
In a laboratory study using an experimental peritoneum model of gastrointestinal cancer, the UFTP [tegafur and uracil (UFT) plus cisplatin] regimen was shown to provide a survival benefit compared with the UFTM (UFT plus mitomycin) regimen that has been considered standard chemotherapy for treatment of advanced carcinoma in Japan. Results indicated that a clinical benefit of the UFTP regimen could be expected. In the pilot clinical study, the UFTP regimen exhibited excellent antitumor effects and seems to improve survival. At present, we are conducting a phase II study in which the UFTP administration schedule was modified to reduce toxicity and secure a similar level of benefit compared with results of the pilot study. Positive results are anticipated.